Neoadjuvant Pembrolizumab for Muscle-Invasive Bladder Cancer with Selective Bladder Sparing

Status: Open to Accrual

Learn more: 

• https://clinicaltrials.gov/study/NCT05406713

Study Contact: studies@hoosiercancer.org; (317) 921-2050.